Increased 18fluoro-2-deoxyglucose (FDG) uptake in the myocardium is frequently observed while performing clinical positron emission tomography (PET) body scans for oncology under fasting conditions. This article reviews the normal variations and abnormal appearances of myocardial FDG accumulation which are likely to be encountered in the routine PET studies. Knowledge about the myocardial glucose metabolism and specific abnormalities are indispensable in the interpretation of myocardial FDG uptake.

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr/92105597DOI Listing

Publication Analysis

Top Keywords

myocardial fdg
12
fdg uptake
12
encountered routine
8
positron emission
8
emission tomography
8
benign variations
4
variations incidental
4
incidental abnormalities
4
myocardial
4
abnormalities myocardial
4

Similar Publications

One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.

Eur J Nucl Med Mol Imaging

January 2025

Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Otfried-Mueller-Str. 14, 72076, Tuebingen, Germany.

Purpose: Somatostatin receptor (SSTR)-PET is crucial for effective treatment stratification of neuroendocrine neoplasms (NENs). In highly proliferating or poorly differentiated NENs, dual-tracer approaches using additional [F]FDG PET can effectively identify SSTR-negative disease, usually requiring separate imaging sessions. We evaluated the feasibility of a one-day dual-tracer imaging protocol with a low activity [F]FDG PET followed by an SSTR-PET using the recently introduced [F]SiFAlin-TATE tracer in a long axial field-of-view (LAFOV) PET/CT scanner and its implications in patient management.

View Article and Find Full Text PDF

Cardiac sarcoidosis; update for the heart failure specialist.

Curr Opin Cardiol

January 2025

Division of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Faculty of Medicine, Tier 1 Clinical Research Chair in Cardiac Electrophysiology, Ottawa, ON, Canada.

Purpose Of Review: This review presents contemporary data on epidemiology, common presentations, investigations and diagnostic algorithms, treatment and prognosis. It particularly focuses on topics of most relevance to heart failure specialists, including what left ventricle (LV) function changes can be expected after treatment and outcomes to all standard and advanced heart failure therapies.

Recent Findings: Around 5% of sarcoidosis patients have clinically manifest cardiac sarcoidosis (CS), presenting with significant arrhythmias (such as conduction disturbances and ventricular arrhythmias) or newly developed unexplained heart failure.

View Article and Find Full Text PDF

Hypertrophic cardiomyopathy (HCM) is a heterogeneous cardiac disease and one of its major challenges is the limited accuracy in stratifying the risk of sudden cardiac death (SCD). Positron emission tomography (PET), through the evaluation of myocardial blood flow (MBF) and metabolism using fluorodeoxyglucose (FDG) uptake, can reveal microvascular dysfunction, ischemia, and increased metabolic demands in the hypertrophied myocardium. These abnormalities are linked to several factors influencing disease progression, including arrhythmia development, ventricular dilation, and myocardial fibrosis.

View Article and Find Full Text PDF

Objectives: We present a case series of patients with granulomatous myocarditis presenting as atrial arrhythmias accompanied by lymphadenopathy.

Background: Atrial myocarditis (AM) may be the cause of atrial fibrillation (AF) in patients without risk factors.

Methods: Patients with atrial fibrillation without risk factors underwent 18F-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET).

View Article and Find Full Text PDF

Acute myocardial infarction (MI) remains a leading cause of mortality worldwide, with inflammatory and reparative phases playing critical roles in disease progression. Currently, there is a pressing need for imaging techniques to monitor immune cell infiltration and inflammation activity during these phases. We developed a novel probe, Tc-HYNIC-mAb, utilizing a monoclonal antibody that targets the voltage-gated potassium channel 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!